India vaccine tycoon calls COVID booster shots 'unethical'
The head of the world's largest vaccine maker said Friday it was 'unethical' to give third doses of the Covid-19 vaccine while developing nations are struggling to access first and second jabs.
Adar Poonawalla is the CEO of Serum Institute of India.The head of the world's largest vaccine maker said Friday it was "unethical" to give third doses of the Covid-19 vaccine while developing nations are struggling to access first and second jabs.
Adar Poonawalla, billionaire chief executive of Serum Institute of India, spoke out as he announced a $4.9 billion deal to take a 15 percent stake in a rival pharma firm, allowing vaccine production to be ramped up.Israel was the first country to recommend Covid-19 booster doses in July and several European nations have since followed, targeting high-risk groups.
The United States, which is suffering rising coronavirus cases, is expected to roll out booster doses from next week."It's unethical to start giving three doses to somebody when others in certain countries and populations have not even got two doses," Poonawalla told reporters. headtopics.com
He added it was "not right" to roll out booster shots when poorer countries have "not been able to get the vaccines purely because the rich nations have taken away most of the vaccines."Serum Institute is currently producing 160 million doses of Astra-Zeneca's Covishield each month, but Poonawalla said this would go up to 200 million from October.
Despite India's export ban because of shortages that have hit the domestic vaccination drive, he said he expects restrictions will "slowly ease in the next month or two".He acknowledged that "some very vulnerable sections" could benefit from booster shots, but added: "There is no evidence to say so far that Covishield requires a third dose."
Serum Institute is taking a stake in fellow pharma billionaire Kiran Mazumdar Shaw's Biocon Biologics.Under the deal, Biocon will be able to manufacture and sell 100 million vaccine doses annually -- including Covishield and Covavax, Serum's Novavax vaccine for children, currently undergoing trials.
Poonawalla said both companies were ramping up research for a potential new-style messenger RNA vaccine, similar to Pfizer and Moderna's Covid-19 products. Read more: Yahoo Singapore »
Covid-19: Coffee shops must designate ‘fixed point’, such as drinks stall, to check patrons’ vaccination status
UNICEF calls for schools to reopen in COVID-19 pandemic-hit nationsMANILA: The United Nations children\u0027s agency UNICEF has urged education authorities to reopen schools as soon as possible in countries where millions of students are still not allowed to return to classrooms 18 months into the COVID-19 pandemic. Schools in around 17 countries remain fully closed, while tho 都没接种疫苗？他们会传播病毒给别人的
About 3,200 vaccinated seniors first to receive Covid-19 booster shots0.2 percent of Americans have died from virus-related causes. Not 'with' covid anymore, but virus related causes - any virus. Are you still believing this crap, scare story? Surely even the intellectually challenged must by now be doubting this...?
Covid-19: 804 new locally transmitted cases; 2 more clusters discovered at nursing homesI really wonder how all the nursing homes are getting infected.I am sure their SOPs are very strict considering the people living in all these homes are aged. The virus seems to know where to “hit” where SOPs are vulnerable..KTVs,Fishery Port,Market/Food Centre,Airports,Malls…
FDA releases documents outlining Pfizer's case for COVID-19 booster shotsThe document from Pfizer shows that a third dose of the vaccine raises levels of neutralising antibodies and sparked no major safety concerns.
Japan firms see economy recovering to pre-COVID level in FY2022: Reuters pollTOKYO : A majority of Japanese firms say the world's third-largest economy will recover to pre-pandemic levels in fiscal 2022, a Reuters poll showed, with many anticipating they will continue to face COVID pains until next year or later. The Corporate Survey results underscored a cautious view of Japan I
Japan firms see economy recovering to pre-COVID level in FY2022TOKYO : A majority of Japanese firms say the world's third-largest economy will recover to pre-pandemic levels in fiscal 2022, a Reuters poll showed, with many anticipating they will continue to face COVID pains until next year or later. The Corporate Survey results underscored a cautious view of Japan I